Simris Alg AB (publ) (SIMRIS-B.ST)
SEK 0.1
(-6.09%)
SEK 0.1
(-6.09%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 38.64 Million SEK | 61.58% |
| 2022 | 23.91 Million SEK | -10.97% |
| 2021 | 26.86 Million SEK | 28.25% |
| 2020 | 20.94 Million SEK | -9.86% |
| 2019 | 23.23 Million SEK | 3.86% |
| 2018 | 22.37 Million SEK | -10.79% |
| 2017 | 25.07 Million SEK | 39.21% |
| 2016 | 18.01 Million SEK | 47.72% |
| 2015 | 12.19 Million SEK | 27.45% |
| 2014 | 9.56 Million SEK | 58.83% |
| 2013 | 6.02 Million SEK | 74.31% |
| 2012 | 3.45 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 9.36 Million SEK | 1.39% |
| 2024 Q2 | 9.59 Million SEK | 2.48% |
| 2023 Q1 | 9.73 Million SEK | -9.65% |
| 2023 Q3 | 9.31 Million SEK | -10.11% |
| 2023 Q2 | 10.36 Million SEK | 6.42% |
| 2023 FY | 38.64 Million SEK | 61.58% |
| 2023 Q4 | 9.23 Million SEK | -0.87% |
| 2022 FY | 23.91 Million SEK | -10.97% |
| 2022 Q2 | 4.84 Million SEK | 14.47% |
| 2022 Q3 | 6.19 Million SEK | 27.76% |
| 2022 Q4 | 10.77 Million SEK | 73.97% |
| 2022 Q1 | 4.23 Million SEK | 16.31% |
| 2021 Q3 | 9.15 Million SEK | 27.4% |
| 2021 Q1 | 6.88 Million SEK | 7.88% |
| 2021 Q2 | 7.18 Million SEK | 4.27% |
| 2021 FY | 26.86 Million SEK | 28.25% |
| 2021 Q4 | 3.64 Million SEK | -60.21% |
| 2020 Q1 | 6.18 Million SEK | 2.9% |
| 2020 FY | 20.94 Million SEK | -9.86% |
| 2020 Q3 | 4.69 Million SEK | 27.16% |
| 2020 Q2 | 3.68 Million SEK | -40.33% |
| 2020 Q4 | 6.38 Million SEK | 36.11% |
| 2019 Q4 | 6 Million SEK | 0.42% |
| 2019 Q3 | 5.98 Million SEK | 10.88% |
| 2019 Q2 | 5.39 Million SEK | -7.76% |
| 2019 Q1 | 5.85 Million SEK | -9.66% |
| 2019 FY | 23.23 Million SEK | 3.86% |
| 2018 Q1 | 5.33 Million SEK | -25.8% |
| 2018 Q3 | 5.32 Million SEK | 1.53% |
| 2018 Q4 | 6.47 Million SEK | 21.67% |
| 2018 FY | 22.37 Million SEK | -10.79% |
| 2018 Q2 | 5.24 Million SEK | -1.76% |
| 2017 FY | 25.07 Million SEK | 39.21% |
| 2017 Q4 | 7.19 Million SEK | 16.66% |
| 2017 Q3 | 6.16 Million SEK | 11.4% |
| 2017 Q2 | 5.53 Million SEK | -10.63% |
| 2017 Q1 | 6.19 Million SEK | 6.99% |
| 2016 Q1 | 4.04 Million SEK | 14.29% |
| 2016 Q2 | 3.98 Million SEK | -1.41% |
| 2016 Q3 | 4.2 Million SEK | 5.6% |
| 2016 FY | 18.01 Million SEK | 47.72% |
| 2016 Q4 | 5.78 Million SEK | 37.57% |
| 2015 Q2 | 3.08 Million SEK | 22.46% |
| 2015 Q3 | 3.06 Million SEK | -0.55% |
| 2015 Q4 | 3.53 Million SEK | 15.37% |
| 2015 Q1 | 2.51 Million SEK | 0.0% |
| 2015 FY | 12.19 Million SEK | 27.45% |
| 2014 FY | 9.56 Million SEK | 58.83% |
| 2013 FY | 6.02 Million SEK | 74.31% |
| 2012 FY | 3.45 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 97.448% |
| Camurus AB (publ) | 1.05 Billion SEK | 96.353% |
| Mendus AB (publ) | 129.13 Million SEK | 70.077% |
| Lipum AB (publ) | 37.3 Million SEK | -3.578% |
| NextCell Pharma AB | -576.01 Thousand SEK | 6808.459% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -36.417% |
| Active Biotech AB (publ) | 44.8 Million SEK | 13.763% |
| Amniotics AB (publ) | 29.07 Million SEK | -32.918% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -163.714% |
| BioArctic AB (publ) | 89.62 Million SEK | 56.886% |
| Cantargia AB (publ) | 290.01 Million SEK | 86.676% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -76.488% |
| CombiGene AB (publ) | 44.14 Million SEK | 12.464% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 72.975% |
| Genovis AB (publ.) | 88.19 Million SEK | 56.187% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 66.42% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -431.673% |
| Intervacc AB (publ) | 79.78 Million SEK | 51.567% |
| Kancera AB (publ) | 63.07 Million SEK | 38.738% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -600.163% |
| LIDDS AB (publ) | 27.75 Million SEK | -39.24% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -432.699% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 71.568% |
| OncoZenge AB (publ) | 15.9 Million SEK | -142.955% |
| Saniona AB (publ) | 1.07 Million SEK | -3487.929% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 87.981% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 89.195% |
| Xintela AB (publ) | 57.31 Million SEK | 32.581% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 78.737% |
| Ziccum AB (publ) | 27.87 Million SEK | -38.611% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -135.608% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 87.417% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 9.359% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -118.526% |
| Corline Biomedical AB | 30.16 Million SEK | -28.089% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 33.411% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 53.538% |
| Aptahem AB (publ) | 10.01 Million SEK | -285.92% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 71.311% |
| Fluicell AB (publ) | 28.61 Million SEK | -35.032% |
| Biovica International AB (publ) | 133.72 Million SEK | 71.103% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -95.26% |
| AcouSort AB (publ) | 25.87 Million SEK | -49.335% |
| Abliva AB (publ) | 27.86 Million SEK | -38.671% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 80.03% |
| 2cureX AB (publ) | 36.51 Million SEK | -5.816% |
| I-Tech AB | 40.14 Million SEK | 3.751% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 95.504% |
| Cyxone AB (publ) | 28.21 Million SEK | -36.96% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 64.668% |
| Biosergen AB | 26.8 Million SEK | -44.138% |
| Nanologica AB (publ) | 69.88 Million SEK | 44.708% |
| SynAct Pharma AB | 224.49 Million SEK | 82.787% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 12.527% |
| BioInvent International AB (publ) | 441.4 Million SEK | 91.246% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -61.316% |
| Alzinova AB (publ) | 36.39 Million SEK | -6.171% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 86.663% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -391.862% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 65.16% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -162.871% |